633 related articles for article (PubMed ID: 28302055)
1. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
Bundhun PK; Yanamala CM; Huang WQ
BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.
Qi-Hua L; Qi Z; Yu Z; Xiao-Long L; Hai-Gang J; Jian-Feng Y; Yi S
Coron Artery Dis; 2015 May; 26(3):259-65. PubMed ID: 25715339
[TBL] [Abstract][Full Text] [Related]
3. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
4. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
[TBL] [Abstract][Full Text] [Related]
5. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
6. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
[TBL] [Abstract][Full Text] [Related]
8. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
[TBL] [Abstract][Full Text] [Related]
9. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
[TBL] [Abstract][Full Text] [Related]
11. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
12. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
[TBL] [Abstract][Full Text] [Related]
13. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
[TBL] [Abstract][Full Text] [Related]
14. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
15. Temporal Trends in the Outcomes of Percutaneous Coronary Intervention With Zotarolimus Eluting Stents Versus Everolimus Eluting Stents: A Meta-Analysis of Randomized Controlled Trials.
Basit J; Ahmed M; Shafiq A; Zaheer Z; Nashwan AJ; Ahmed A; Hamza M; Naseer U; Ali S; Gupta N; Sattar Y; Kawsara A; Daggubati R; Alraies MC
Clin Cardiol; 2024 Jun; 47(6):e24306. PubMed ID: 38888152
[TBL] [Abstract][Full Text] [Related]
16. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
18. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
Kim Y; Oh SS; Jeong MH; Ahn Y; Kim JH; Hong YJ; Sim DS; Kim MC; Kim HS; Yun KH; Oh SK; Kim CJ; Cho MC
Cardiol J; 2019; 26(5):469-476. PubMed ID: 29745969
[TBL] [Abstract][Full Text] [Related]
19. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]